Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model | Scientific Reports
PERIDOT – Patient ExpeRIence in fabry Disease On venglustaT | M.A.G.I.C Clinic
Venglustat | C20H24FN3O2S | CID 60199242 - PubChem
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers - Peterschmitt - 2021 - Clinical Pharmacology in Drug Development - Wiley Online Library
Pharmacokinetics, Safety, and Tolerability of Single-Dose Orally Administered Venglustat in Healthy Chinese Volunteers | SpringerLink
Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model | Scientific Reports
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update - IOS Press
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020. - Abstract - Europe PMC
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update - IOS Press
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020 - IOS Press
Ziv Gan-Or on Twitter: "Despite being completely unclear whether glucosylceramide is relevant is PD, the plans for the trial continued as usual. Now, let's talk about some pre-clinical results, using mouse "PD
%20for%20Fabry%20Disease.png?md=1 "Venglustat (GZ402671) for Fabry Disease Clinical Trial 2023 | Power")
Venglustat (GZ402671) for Fabry Disease Clinical Trial 2023 | Power
Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model | Scientific Reports
PDF) Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers
Sanofi's venglustat fails another trial, ending pursuit of kidney disease | Fierce Biotech
Venglustat, an orally administered glucosylceramide synthase inhibitor: Assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study - ScienceDirect
IJMS | Free Full-Text | Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative Disorders
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update - IOS Press
Frontiers | Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies
![Top 10 Fabry Disease Clinical Trials [2023 Studies] | Power](https://pwr-og-img.withpower.com/Fabry%20Disease%20research%20studies%20recruiting%20patients%20in%202023%20need%20your%20help.%20Receive%20premium%20care%20&%20cutting%20edge%20treatments%20by%20enrolling%20in%20fabry%20disease%20clinical%20trials%20today..png?md=1 "Top 10 Fabry Disease Clinical Trials [2023 Studies] | Power")
Top 10 Fabry Disease Clinical Trials [2023 Studies] | Power
Progress towards therapies for disease modification in Parkinson's disease - The Lancet Neurology
Precision medicine in Parkinson's disease: emerging treatments for genetic Parkinson's disease. - Abstract - Europe PMC
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020 - IOS Press
Ibiglustat (L-Malic acid) (Venglustat (L-Malic acid)) | Glucosylceramide Synthase Inhibitor | MedChemExpress
